题名 | A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations |
作者 | |
发表日期 | 2023-06-15 |
发表期刊 | Cancer communications (London, England) 影响因子和分区 |
语种 | 英语 |
原始文献类型 | Letter |
ISSN | 2523-3548 |
卷号 | 43期号:9 |
DOI | 10.1002/cac2.12456 |
收录类别 | PUBMED |
URL | 查看原文 |
PubMed ID | 37322852 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/181173 |
专题 | 第一临床医学院(信息与工程学院)、附属第一医院_内科学_呼吸与危重症医学科 |
作者单位 | 1.Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.; 2.Department of Respiratory Medicine, Xiangya Hospital Central South University, Changsha, Hunan, P. R. China.; 3.Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.; 4.Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai, P. R. China.; 5.Department of Respiratory Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, P. R. China.; 6.Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China.; 7.Department of Medical Thoracic Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou, Zhejiang, P. R. China.; 8.Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P. R. China.; 9.Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, P. R. China.; 10.Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P. R. China.; 11.Huadong Global Development Center, Hangzhou ZhongMei HuaDong Pharmaceutical Company, Hangzhou, Zhejiang, P. R. China.; 12.Department of Respiratory Medicine, General Hospital of Eastern Theater Command, Nanjing, Jiangsu, P. R. China.; 13.Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang, P. R. China. |
推荐引用方式 GB/T 7714 | Pingli Wang,Liming Cao,Panwen Tian,et al. A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations[J]. Cancer communications (London, England),2023,43(9). |
APA | Pingli Wang., Liming Cao., Panwen Tian., Shengxiang Ren., Liyun Miao., ... & Kai Wang. (2023). A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations. Cancer communications (London, England), 43(9). |
MLA | Pingli Wang,et al."A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations".Cancer communications (London, England) 43.9(2023). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论